These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23805176)

  • 1. Cost-Effectiveness of a Community Pharmacist-Led Sleep Apnea Screening Program - A Markov Model.
    Perraudin C; Le Vaillant M; Pelletier-Fleury N
    PLoS One; 2013; 8(6):e63894. PubMed ID: 23805176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of intervention led by a community pharmacist for improving recognition of sleep apnea in primary care--a cohort study.
    Perraudin C; Fleury B; Pelletier-Fleury N
    J Sleep Res; 2015 Apr; 24(2):167-73. PubMed ID: 25178456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility of three approaches to the diagnosis of sleep apnea: polysomnography, home testing, and empirical therapy.
    Chervin RD; Murman DL; Malow BA; Totten V
    Ann Intern Med; 1999 Mar; 130(6):496-505. PubMed ID: 10075617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Analysis of Preoperative Screening Strategies for Obstructive Sleep Apnea among Patients Undergoing Elective Inpatient Surgery.
    Sankar A; Dixon PR; Sivanathan L; Memtsoudis SG; de Almeida JR; Singh M
    Anesthesiology; 2020 Oct; 133(4):787-800. PubMed ID: 32930728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea.
    Mar J; Rueda JR; Durán-Cantolla J; Schechter C; Chilcott J
    Eur Respir J; 2003 Mar; 21(3):515-22. PubMed ID: 12662011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea.
    Pietzsch JB; Garner A; Cipriano LE; Linehan JH
    Sleep; 2011 Jun; 34(6):695-709. PubMed ID: 21629357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-utility of screening for depression in primary care.
    Valenstein M; Vijan S; Zeber JE; Boehm K; Buttar A
    Ann Intern Med; 2001 Mar; 134(5):345-60. PubMed ID: 11242495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis.
    McDaid C; Griffin S; Weatherly H; Durée K; van der Burgt M; van Hout S; Akers J; Davies RJ; Sculpher M; Westwood M
    Health Technol Assess; 2009 Jan; 13(4):iii-iv, xi-xiv, 1-119, 143-274. PubMed ID: 19103134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pharmacist-Led Deprescribing of NSAIDs in Community-Dwelling Older Adults.
    Sanyal C; Turner JP; Martin P; Tannenbaum C
    J Am Geriatr Soc; 2020 May; 68(5):1090-1097. PubMed ID: 32105355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.
    Chomsky-Higgins Menut K; Pearlstein SS; Conroy PC; Roman SA; Shen WT; Gosnell J; Sosa JA; Duh QY; Suh I
    Surgery; 2022 Jan; 171(1):96-103. PubMed ID: 34238603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
    Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
    Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
    Villacorta R; Hay JW; Messali A
    Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada.
    Pullagura GR; Waite NM; Houle SKD; Violette R; Wong WWL
    J Am Pharm Assoc (2003); 2019; 59(4):489-497.e1. PubMed ID: 30979576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation.
    Ankcorn MJ; Tedder RS; Cairns J; Sandmann FG
    Value Health; 2020 Mar; 23(3):309-318. PubMed ID: 32197726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.